Table 1

Characteristics of the patients at inclusion

Patients with systemic sclerosis

(n = 137)


Age (years)

54.8 ± 12.9

Female, n (%)

125 (91.2)

Duration of SSc disease (years)

12.2 ± 12.0

Diffuse, n (%)

42 (31)

Modified Rodnan skin score

8.1 ± 6.0

Myalgia, n (%)

77 (56)

DLCO (% pred)

64 ± 17

ILD, n (%)

51 (37.1)

ATA, n (%)

37 (27)

ACA, n (%)

62 (45)

Anti U1-RNP antibody

8 (5.8)

Anti U3-RNP antibody

6 (4.3)

Anti PM-Scl antibody

5 (3.6)

Anti RNA polymerase III antibody

4 (2.9)

C-reactive protein (mg/L)

5.2 ± 7.6

Plasma aspartate transaminases (0 to 32 U/L)

23.1 ± 9.3

Plasma alanine transaminases (0 to 32 U/L)

21.5 ± 14.0

Plasma aldolase (0 to 7 U/L)

10.3 ± 7.5

Plasma creatine kinase (0 to 160 U/L)

111.1 ± 142.1

Immunosuppressive treatment, n (%)

18 (13)


% of pred, percentage of predicted value; ACA, Anti-centromere antibodiy; U3-RNP, Anti U3-RNP antibody; anti-PM-Scl, anti-polymyositis-scleroderma antibody; ATA, Anti-topoisomerase I antibody; DLCO, diffusing capacity of carbon monoxide; ILD, interstitial lung disease; PM-Scl, polymyositis scleroderma; sPAP, Systolic pulmonary artery pressure assessed by echocardiogram; U1-RNP, U1-ribonucleic protein. Among 18 patients with immunosuppressive therapy, nine had corticosteroid dose less than 10 mg/day.

Tolédano et al. Arthritis Research & Therapy 2012 14:R152   doi:10.1186/ar3888

Open Data